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Abstract
Background: Candida krusei infections are associated with high mortality. In order to explore
ways to prevent these infections, we investigated potential routes for nosocomial spread and
possible clonality of C. krusei in a haematological unit which had experienced an unusually high
incidence of cases.
Methods: We searched for C. krusei contamination of the hospital environment and determined
the level of colonization in patients and health care workers. We also analyzed the possible
association between exposure to prophylactic antifungals or chemotherapeutic agents and
occurrence of C. krusei. The C. krusei isolates found were genotyped by pulsed-field electrophoresis
method in order to determine possible relatedness of the cases.
Results:  Twelve patients with invasive C. krusei infection and ten patients with potentially
significant infection or mucosal colonization were documented within nine months. We were
unable to identify any exogenic source of infection or colonization. Genetic analysis of the isolates
showed little evidence of clonal transmission of C. krusei strains between the patients. Instead, each
patient was colonized or infected by several different closely related genotypes. No association
between medications and occurrence of C. krusei was found.
Conclusion: Little evidence of nosocomial spread of a single C. krusei clone was found. The
outbreak may have been controlled by cessation of prophylactic antifungals and by intensifying
infection control measures, e.g. hand hygiene and cohorting of the patients, although no clear
association with these factors was demonstrated.
Background
Candida infections are common in immunocompromized
host and result in significant mortality and extended hos-
pital treatement [1-3]. An increase in prevalence of species
of Candida other than C. albicans, such as Candida glabrata
and Candida krusei, has been recognized in some hospitals
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while they are still rare in many other institutions [4-10].
A number of fungal pathogens are inherently resistant to
fluconazole and amphotericin B and require alternative
antifungals, such as echinocandins or the newer azoles. It
is speculated that use of these agents may in turn contrib-
ute to further selection pressure towards these fungi and
may therefore partially explain, for example, an increase
in the occurrence of zygomycoses. Invasive infections or
colonization with C. krusei has been associated with pro-
phylactic use of antifungals [4,11,12]. It is thought that
suppression of common Candida species with fluconazole
prophylaxis may allow the growth of less pathogenic and
inherently resistant or less susceptible species of Candida.
The role of the prophylactic fluconazole, however, has not
been evident in all outbreak settings and other antimicro-
bial agents may contribute to colonization with the spe-
cies of Candida other than C. albicans [13-15].
Clonal spread of C. albicans has been verified in a number
of outbreak situations [7,16,17]. Candida parapsilosis is a
common finding on healthy hands and clonal nosoco-
mial spread on the hands of health care workers has been
demonstrated [18,19]. There is some evidence supporting
nosocomial transmission of a C. krusei clone between
patients and health care workers although genotyping of
small numbers of C. krusei isolates during the outbreaks
has not been able to exclude the possibility of nosocomial
spread of C. krusei clones [12,20,21]. A recent cluster of
infections was shown to be caused by clonal spread of a
single  C. krusei strain [4]. Mechanisms of nosocomial
spread of C. krusei, however, remain unclear.
In the present study, we have analyzed a cluster of cases
with C. krusei infection or colonization in a haematologi-
cal unit in which the frequency of confirmed invasive Can-
dida infections has been low and C. krusei has been a
rarity. We have searched for potential modes of nosoco-
mial transmission of C. krusei between patients and health
care workers, and within the environment. In addition, we
have investigated possible clonality of the C. krusei by gen-
otyping the isolates collected during the outbreak.
Methods
Patients and settings
Oulu University Hospital (OUH) is a tertiary care hospital
serving a population of 724600 in Northern Finland. The
haematological unit of OUH, with total of 928 admis-
sions in 2005, is responsible for treatment of acute leukae-
mia within that region. 424 admission were due to
haematological malignancies and 504 admissions were
general internal medicine cases. Eighteen new acute leu-
kaemia cases were diagnosed in 2005 and seven of them
underwent allogeneic bone marrow transplantation. In
addition, five cases of acute leukaemia relapses were rec-
ognized in 2005 but none of them received an allogeneic
transplant. The average length of hospitalization was 10.8
days for haematological patients and 3.6 days for patients
with other diagnoses. The ward has 20 beds in 11 rooms
including 6 isolation units. The unit is operated by two
clinical haematologists, one resident in haematology, and
21 nurses working in shifts. In addition, doctors working
in various specialties, physiotherapists, and laboratory
personnel, for example, are in frequent contact with the
patients in the ward.
Candida infections and usage of antifungals
An unusually high number of C. krusei findings was
recorded in the haematological unit in February 2005.
Before recognition of the outbreak, confirmed invasive
infections caused by Candida species were rare in the unit:
there were four blood culture positive patients with C.
albicans  and one patient with C. krusei during 2000 –
2004. Prophylactic fluconazole (400 mg po) was given
during neutropenia to several patients that were being
considered for allogeneic bone marrow transplantation.
Empiric treatment with amphotericin B (conventional or
liposomal) was started typically on the fourth day of per-
sisting neutropenic fever. In order to analyze the possible
association between antifungal prophylaxis and occur-
rence of C. krusei, data of exposure to fluconazole use was
collected from the medical records. The pearson Chi-
Square test was used to analyze the significance of fluco-
nazole exposure.
Microbiological samples
Weekly rectal and pharyngeal swabs were collected for
yeast culture in order to follow Candida colonization in
patients receiving chemotherapy from April 2005 until
the end of November 2005. Hand colonization in patients
in which the rectal or pharyngeal swabs were positive for
C. krusei were sampled for yeasts. Pharyngeal and rectal
samples were also collected from the health care workers
in the unit in order to determine possible colonization
with C. krusei or other Candida species. Environmental
samples were collected from all wet and humid locations
that were considered to be potential sources of C. krusei
colonization in the ward. Shower heads, taps, sinks, man-
holes, and sink traps were examined by selective cultures
for yeast and aerobic bacteria.
Identification of Candida species
Candida species were isolated from the samples on Sab-
ouraud Dextrose agar and identified by standard morpho-
logical and biochemical methods. A total of 97 C. krusei
clones were stored at -80°C in skimmed milk and 35 of
them were subcultured on Saboraud agar for molecular
typing.BMC Infectious Diseases 2007, 7:97 http://www.biomedcentral.com/1471-2334/7/97
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Molecular typing of the Candida krusei isolates
DNA preparation for CHEF electrophoresis was done with
a CHEF Mammalian Genomic DNA Plug kit (Bio-Rad,
Hercules, CA) accordingly to the manufacturers instruc-
tions. Restriction endonuclease digestion was performed
overnight at 50°C in buffer containing 2 U of SfiI. CHEF
pulsed-field electrophoresis was performed at 13°C for 24
h at 6 V/cm in a 1,2% SeaKem Gold agarose gel (FMC Bio-
Produtcs); the pulse-times varying from 10 to 90 seconds.
The gels were stained with ethidium bromide and cluster
analysis was done with BioNumerics v4.5 (Applied
Maths) using the Dice coefficient to analyze the similarity
of the banding patterns, and the unweighted pair group
method using arithmetic averages (UPGMA) for cluster
analysis. A similairity cutoff of 90% was used to identify
genotypes.
Results
Outbreak description and infection control measures 
taken
In February 2005, an increase in the number of culture-
confirmed C. krusei infections was recognized in the hae-
matological ward. There were six blood culture positive
cases (Table 1, patients 1 – 6) and in addition, six patients
had significant C. krusei growth in samples obtained from
deep locations although the blood cultures were negative
(Table 1, patients 7 – 12). In three haematology patients
the clinical presentation was consistent with invasive fun-
gal infection and they were colonized by C. krusei (Table
1, patients 13 – 15). In seven patients the C. krusei find-
ings were considered to represent colonization (Table 1,
patients 16 – 22) that had to be taken into account regard-
ing empirical antifungal treatment in the persence of per-
sisting neutropenic fever. After recognition of the
potential outbreak, intensive use of alcohol-based hand
hygiene (70 % alcohol) was encouraged and consump-
tion of the hygiene products was followed. Weekly sur-
veillance of pharyngeal and rectal colonization of all
haematology patients for C. krusei was started in April
2005 and colonized patients were cohorted according to
the surveillance findings. The weekly surveillance cultures
were collected until the end of November 2005. Since
then, a high number cultures have been taken from
patients in which superficial or deep Candida infection
was suspected. No new clinical infection or colonization
by C. krusei has been found.
Microbiological findings
All haematological patients (a total of 70) were screened
for colonization by Candida (Table 2). C. albicans was the
most common species followed by C. krusei which was
found from 5.2 to 25.7 % of the patients in pharyngeal or
Table 1: The table describes the location of C. krusei isolation in patients with either confirmed invasive infection, patients with 
potentially significant infection, or patients with C. krusei colonization. 
Patient sex, age Diagnosis C. krusei isolation
1F  3 2 A M L B S I
2M  6 2 A M L B S I
3 M 71 duodenal carcinoma BSI
4 F 46 mastocytosis BSI
5 F 64 abdominal surgery BSI
6M  8 6 C L L B S I
7 M 53 AML peritoneum
8 M 22 ALL peritoneum
9 M 33 AML oesophagus
10 M 39 AML kidney, liver
11 F 53 AML invasive candidiasis in autopsy
12 M 55 AML invasive candidiasis in autopsy
13 F 62 AML typhlitis, pneumonia
14 M 67 AML aortitis, pneumonia
15 M 69 multiple myeloma severe mucositis
16 F 59 AML rectum, pharynx
17 F 66 MDS rectum, pharynx
18 F 59 lymphoma rectum, pharynx
19 F 70 MDS rectum, pharynx
20 M 22 toxic reaction* rectum, pharynx
21 M 21 eosinophilic leukaemia rectum, pharynx
22 M 65 AML rectum, pharynx
M, male; F, female; BSI, blood stream infection; AML, acute myeloid leukaemia; ALL, acute lymphatic leukaemia; CLL, chronic lymphatic leukaemia; 
MDS, myelodysplastic syndrome. 
*The toxic reaction refers to bone marrow suppression due to alcohol abuseBMC Infectious Diseases 2007, 7:97 http://www.biomedcentral.com/1471-2334/7/97
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rectal samples. Patients that were positive for C. krusei in
their pharyngeal or rectal swabs, did not carry C. krusei on
their hands.
A total of 21 health care workers were screened for pha-
ryngeal and rectal C. krusei colonization. Fifty-five % of
the health care workers were colonized by C. albicans in
their rectum and 62 % in their pharynx. None of them
were colonized by C. krusei (Table 3).
Environmental samples from the haematological ward
were collected from wet and humid locations that were
considered to be potential sites of C. krusei colonization.
Very little C. krusei contamination was found (Table 4).
Two locations (sink traps) in a room that was occupied by
a C. krusei carrier, grew C. krusei. None of the incoming
water sources or shower heads were positive for C. krusei.
Genotyping of the C. krusei isolates
A total of 35 C. krusei isolates from 18 patients were ana-
lyzed by genotyping. This represented single isolations
from 12 patients and 23 repeat isolations (2 to 5 isolates
from 7 patients each) from clinically significant findings
or those isolated from weekly surveillance cultures. Geno-
typing of these strains showed little evidence of clonal
transmission of C. krusei. Instead, each patient was colo-
nized or infected by several different closely related geno-
types indicated by minor genotypic variation between the
repeat isolates collected from individual patients. Some
clustering of the genotypes, however, could be obversed
(shown in Figure 1). Clones isolated from blood (Patients
1 – 6) were genetically within the same cluster. In addi-
tion, using the similarity cut-off of 90%, five groups of
patients with similar C. krusei strains could be found
(patients 1 and 5; patients 20, 21, and 8; patients 1, 3, and
4; patients 8 and 9, patients 9 and 10). Our PFGE typing
method showed good discriminatory power and repro-
ducibility between the runs in our study [22].
Exposure to fluconazole
Fluconazole therapy had been given to twelve of the 22
patients from whom C. krusei had been isolated. Eight of
the twelve patients, in which C. krusei finding was consid-
ered clinically significant, were exposed to fluconazole.
Eight of the thirteen patients that were treated for acute
leukaemia, received fluconazole. During the same time
period, nineteen patients with acute leukaemia, that were
not colonized by C. krusei, was identified and twelve of
them received fluconazole. Statistical analysis shows no
association between the fluconazole exposure and C. kru-
sei in acute leukaemia patients (p = 0.598, Pearson Chi-
Square test). In addition, in the haematology patients that
were screened for C. krusei there was no association with
the fluconazole exposure and isolation of C. krusei (p =
0.213). Regardless of this, the prophylactic use of flucona-
zole was stopped and all antifungals were used solely for
either empiric treatment of persisting neutropenic fever or
proven fungal infections. The patients positive for C. kru-
sei received either caspofungin or voriconazole as empiric
antifungal treatment.
Discussion
Invasive infections caused by C. krusei has been associated
with adverse outcome [23,24]. Poor response to treament
may lead to extended hospitalization and economical
burden. Therefore, control of emergence of C. krusei and
other resistant fungal pathogens should be a priorioty.
Understanding of risk factors and routes of transmission
should help clinicians to prevent infections or to deal with
a cluster of infections by C. krusei.
Table 2: Candida colonization of the haematological patients. 
04/2005
(n = 55)
05/2005
(n = 112)
06/2005
(n = 76)
09/2005
(n = 35)
10/2005
(n = 136)
11/2005
(n = 109)
Candida albicans 43.6 54.5 50 62.8 70.6 70.6
Candida glabrata 00001 . 5 8 . 3
Candida krusei 7.2 11.6 5.2 25.7 19.1 13.8
Candida tropicalis 3 . 6 0 . 9 0000
Candida 
norwegiansis
00 . 9 0000
Candida 
guillermondii
002 . 6 5 . 7 00
Candida parapsilosis 00002 . 8 0
Geotrichum spp 10.9 8.9 6.6 5.7 5.8 0
Fusarium spp 0 . 2 0 . 9 0000
negative 25.5 42.9 52.6 22.9 21.3 22.0
The table shows percentages of surveillance cultures that were positive for fungal species. The samples were collected during April 2005 (04/2005) 
to November 2005 (11/2005). Some samples grew several fungal species. 
Number of cultures (n) is shown in parenthesis.BMC Infectious Diseases 2007, 7:97 http://www.biomedcentral.com/1471-2334/7/97
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It has been shown that cross-contamination of both
health care workers and patients by multiple strains of C.
albicans  is possible [25]. C. parapsilosis has also been
shown to colonize hands of health care workers which
may lead to clonal spread of the pathogen to vulnerable
patients [19]. Our patients, that were positive for C. krusei
in their pharyngeal or rectal samples, did not have C. kru-
sei growth on their hands. Health care workers at the ward
were also screened and C. krusei was not isolated from any
pharyngeal or rectal samples. In addition, careful analysis
of environmental samples for C. krusei did not reveal any
significant positive results. The incoming water sources
were negative for C. krusei and we speculate that the C.
krusei growth in the two sewage samples was an unlikely
source of infection. These data do not support the possi-
bile route of clonal transmission by hand contact or from
a single environmental source. It must be appreciated,
however, that the negative culture results may not rule out
occasional exposure of patients or health care workers to
C. krusei in the ward. Although we were unable demon-
strate transmission by hand contact, we continue to
emphasize the importance of stringent hand hygiene
measures at the ward.
Prophylactic use of fluconazole has been associated with
invasive infection or colonization by C. krusei although
opposing views has been presented [4,11,12,15]. In our
study, about half of the patients with acute leukaemia,
that were infected or colonized by C. krusei, were exposed
to fluconazole. The same proportion of leukaemia
patients that were negative for C. krusei, had been exposed
to fluconazole. We have also examined the possible asso-
ciation between the occurrence of C. krusei and the use of
antifungal agents or drugs used for the treatment of leu-
kaemia. Overall, we were unable to demonstrate any asso-
ciation between the medications and occurrence of C.
krusei. It is possible that higher number of cases might
have revealed such a relationship.
In a previous study, molecular typing of C. krusei isolates
suggested that clonal spread of a single strain caused an
outbreak [4]. Genetic analysis of our C. krusei isolates
from individual patients suggests mainly for an unrelated
origin. Genotyping of several sequential isolates from five
patients revealed that each patient harboured their own
strain or a slightly altered variant throughout the study
period (Figure 1). Some clustering of the genotypes, how-
ever, could be observed. Interestingly, the C. krusei clones
isolated from blood cultures (Figure 1, patients 1–6) were
within the same genetic cluster suggesting that those
strains may share properties with each other. According to
genotyping, we conclude that several different C. krusei
strains are capable of colonizing the intestinal tract that
may serve as an origin of the infection [26].
Most of our patients with C. krusei invasion had signifi-
cant injury of mucosa from which the infection was most
likely acquired. Surveillance of mucosal colonization by
C. krusei was continued until no new invasive infections
occurred. Thereafter, we have not found any new cases
Table 3: Rectal and pharyngeal samples were collected from health care workers and fungal growth was analyzed.
Species rectum (n = 20) pharynx (n = 21)
Candida albicans 11 13
Geotrichum 10
Saccharomyces cerevisae 10
The table shows the number of health care workers positive for the fungal isolates.
Table 4: Culture findings in the enviromental samples collected from wet or humid locations in the ward. 
Species tap/incoming water (n = 62) sink trap (n = 16) surface (n = 6)
Fusarium spp 23 10 3
Rhodotorula spp 11 0 0
Geotrichum spp 131
Candida albicans 131
Candida parapsilosis 100
Candida krusei 020
Candida tropicalis 100
Aspergillus spp 110
Saccharomyces spp 010
The table shows culture findings for incoming water sources, sink traps, or on humid surfaces. Number of samples (n) taken from each location is 
shown in parenthesis.BMC Infectious Diseases 2007, 7:97 http://www.biomedcentral.com/1471-2334/7/97
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Dendrogram of isolates based on the Dice coefficient, obtained by SfiI macrorestriction analysis of C. krusei isolates Figure 1
Dendrogram of isolates based on the Dice coefficient, obtained by SfiI macrorestriction analysis of C. krusei isolates. The sym-
bols (dot, star, diamond) in the dendogram indicate three large clonal groups identified by PFGE.
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despite of the high number of samples that have been col-
lected whenever fungal infection was suspected. We spec-
ulate that cessation of antifungal prophylaxis with
fluconazole and an increased awareness of infection con-
trol measures, e.g. hand hygiene and cohorting of the
patients, may have been beneficial although we were una-
ble to demonstrate the significance of any single measure.
Conclusion
Our data indicate that several different C. krusei isolates
may colonize immunocompromized patients. It seems
unlikely that the C. krusei colonization of the patients
would have originated from contamined hospital envi-
ronment or the health care workers. We speculate that ces-
sation of antifungal prophylaxis and an increased
awareness of infection control measures may have been
favorable procedures in order to control the outbreak.
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